Albuvirtide-based regimens for advanced- stage HIV and Talaromyces marneffei co-infection: A longitudinal case series
International Journal of STD & AIDS · 2026-07 · 37 (8) · 846-852
DOI: 10.1177/09564624261440690 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of STD & AIDS, online erschienen am 07.04.2026. Verfasst von Xiaoshu Yu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Baise People's Hospital, Baise, China. Hauptthemen laut MEDLINE: HIV Infections, Talaromyces, Coinfection, Mycoses. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Baise City Science and Technology Development Plan Project.
Abstract (Originalsprache)
Objective
Talaromyces marneffei (TM) represents a major opportunistic infection among People living with HIV (PLWH) in Southeast Asia and southern China. This study aimed to evaluate the efficacy and safety of Albuvirtide (ABT, currently licensed only in China)-based antiretroviral regimens during the advanced stage of infection in this understudied population.
Methods
We conducted a longitudinal case series from June 2022 to March 2024 at two hospitals in Guangxi, China. The study included treatment-naive HIV/TM co-infected patients who initiated ABT-based antiretroviral therapy combined with oral background regimens (predominantly dolutegravir/lamivudine or bictegravir/emtricitabine/tenofovir alafenamide). Analyses and findings evaluated after 6 weeks of treatment included changes in HIV viral load, CD4 + T-cell count, and CD4/CD8 ratio. Data were analyzed using Wilcoxon signed-rank and McNemar’s tests.
Results
A total of 52 patients were included. Excluding one patient lost to follow-up, the 6-week survival rate was 98.0% (50/51), with a single mortality attributed to advanced disease. In the 50 patients analyzed, the median viral load decreased rapidly from 274,500 (IQR: 52,775-794,874) to 119.5 (IQR: 40-464.5) copies/mL (P < 0.001). The median CD4 + T-cell count increased significantly from 14.0 (IQR: 5.0-32.0) to 83.5 (IQR: 35.0-127.75) cells/μL (P < 0.001). The CD4/CD8 ratio showed an improving trend (0.065 to 0.100, P = 0.058). No severe adverse events related to the study drugs were observed.
Conclusion
Findings from this small case series suggest that ABT-based regimens demonstrated a favorable safety profile and achieved rapid viral suppression during the critical advanced stage of HIV/TM co-infection. These findings suggest that adding parenteral ABT to oral background regimens provides a feasible and intensified treatment strategy to stabilize critically ill patients, particularly those with potential gastrointestinal dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Baise People's Hospital, Baise, China.
- The Fourth People's Hospital of Nanning, Nanning, China.
ORCID-Profile: Jun Zou
Förderung
- Baise City Science and Technology Development Plan Project
Zitieren
APA
Yu, X., Li, S., Zhou, C., Ma, Q., Lu, P., Ma, F., Song, C., Nong, W., Lu, Y., Tan, L., He, J., & Zou, J. (2026). Albuvirtide-based regimens for advanced- stage HIV and Talaromyces marneffei co-infection: A longitudinal case series. International Journal of STD & AIDS, 37(8), 846-852. https://doi.org/10.1177/09564624261440690
Vancouver
Yu X, Li S, Zhou C, Ma Q, Lu P, Ma F, et al. Albuvirtide-based regimens for advanced- stage HIV and Talaromyces marneffei co-infection: A longitudinal case series. International Journal of STD & AIDS. 2026;37(8):846-852. doi:10.1177/09564624261440690
BibTeX
@article{Yu2026,
author = {Yu, Xiaoshu and Li, Shengyi and Zhou, Changjing and Ma, Qinge and Lu, Pingxuan and Ma, Fuyan and Song, Cong and Nong, Wenjun and Lu, Yansi and Tan, Lianlian and He, Jingjing and Zou, Jun},
title = {Albuvirtide-based regimens for advanced- stage HIV and Talaromyces marneffei co-infection: A longitudinal case series},
journal = {International Journal of STD & AIDS},
year = {2026},
volume = {37},
number = {8},
pages = {846--852},
doi = {10.1177/09564624261440690}
}
EUVIMED